These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 30110263)

  • 1. Efficacy and Safety of Oral Alendronate Treatment in Children and Adolescents with Osteoporosis.
    Unal E; Abaci A; Bober E; Büyükgebiz A
    J Pediatr Endocrinol Metab; 2006 Apr; 19(4):523-528. PubMed ID: 38742779
    [No Abstract]   [Full Text] [Related]  

  • 2. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation.
    Imai K
    Clin Interv Aging; 2013; 8():681-8. PubMed ID: 23766643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of bisphosphonate with bone loss and pain-related behaviour in an adjuvant-induced osteoporosis model.
    Mayumi N; Wakabayashi H; Miyamura G; Sudo A
    Mod Rheumatol; 2024 Jul; 34(4):841-850. PubMed ID: 37616510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study.
    Lee WY; Sun LM; Lin MC; Liang JA; Chang SN; Sung FC; Muo CH; Kao CH
    PLoS One; 2012; 7(12):e53032. PubMed ID: 23300854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosamax Fractures-Justice Has Not Been Served.
    Curfman G
    JAMA; 2024 Jun; 331(22):1887-1888. PubMed ID: 38748439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab in the treatment of osteoporosis associated with chronic kidney disease.
    Covic A; Apetrii M
    Lancet Diabetes Endocrinol; 2024 Apr; 12(4):225-227. PubMed ID: 38373426
    [No Abstract]   [Full Text] [Related]  

  • 7. Ångstrom-scale gold particles loaded with alendronate via alpha-lipoic acid alleviate bone loss in osteoporotic mice.
    Gao W; Li JJ; Shi J; Lan H; Guo Y; Fu D
    J Nanobiotechnology; 2024 Apr; 22(1):212. PubMed ID: 38689294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs for pre-osteoporosis: prevention or disease mongering?
    Alonso-Coello P; García-Franco AL; Guyatt G; Moynihan R
    BMJ; 2008 Jan; 336(7636):126-9. PubMed ID: 18202066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Boxed Warning for Osteoporosis Drug.
    Aschenbrenner DS
    Am J Nurs; 2024 Jun; 124(6):18. PubMed ID: 38780333
    [No Abstract]   [Full Text] [Related]  

  • 10. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis.
    Armamento-Villareal R; Napoli N; Panwar V; Novack D
    N Engl J Med; 2006 Nov; 355(19):2048-50. PubMed ID: 17093260
    [No Abstract]   [Full Text] [Related]  

  • 11. Alendronate for the treatment of osteoporosis in men.
    Olszynski WP; Davison KS
    Expert Opin Pharmacother; 2008 Feb; 9(3):491-8. PubMed ID: 18220499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence on atherosclerosis of improvement of bone mineral density after medication for osteoporosis].
    Yamada S; Inaba M; Nishizawa Y
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():348-51. PubMed ID: 18161129
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of Short Term Alendronate Administration on Bone Mineral Density in Patients with Chronic Kidney Disease.
    Aggarwal HK; Jain D; Chhabra P; Yadav RK
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2018 Jul; 39(1):5-13. PubMed ID: 30110263
    [No Abstract]   [Full Text] [Related]  

  • 14. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
    N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [When should bisphosphonate treatment be discontinued?].
    Eriksen EF; Halse J
    Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.